Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Leases (2021 - 2025)

Prime Medicine filings provide 5 years of Current Leases readings, the most recent being $8.1 million for Q4 2025.

  • On a quarterly basis, Current Leases rose 125.15% to $8.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.1 million, a 125.15% increase, with the full-year FY2025 number at $8.1 million, up 125.15% from a year prior.
  • Current Leases hit $8.1 million in Q4 2025 for Prime Medicine, up from $7.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $13.5 million in Q2 2023 to a low of $3.6 million in Q4 2024.
  • Median Current Leases over the past 5 years was $7.7 million (2025), compared with a mean of $8.4 million.
  • Biggest five-year swings in Current Leases: tumbled 61.39% in 2024 and later soared 125.15% in 2025.
  • Prime Medicine's Current Leases stood at $7.3 million in 2021, then surged by 59.41% to $11.7 million in 2022, then fell by 20.68% to $9.3 million in 2023, then crashed by 61.04% to $3.6 million in 2024, then soared by 125.15% to $8.1 million in 2025.
  • The last three reported values for Current Leases were $8.1 million (Q4 2025), $7.7 million (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.